Stockreport

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 [Yahoo! Finance]

PepGen Inc.  (PEPG) 
PDF – Conference call scheduled today at 8:00 a.m. ET – BOSTON, February 24, 2025 BUSINESS WIRE )--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company adva [Read more]